Fundamental Applied Biology (FAB) received $500,000 for the development of its cell-free protein synthesis technology toward commercialization. This SBIR phase IIB grant comes from the NSF.

During the STTR phase I and phase II NSF projects, FAB reported that certain proteins could be made in a soluble form through a cell-free system that was controllable and efficient. With the current award, FAB will continue to develop the technology with a market-driven, therapeutic protein as FAB’s first target product.

“The grant will allow FAB to further develop and optimize our cell-free technology to enable the production of pharmaceutical protein therapeutics with the goal of improving their biological activity,” says Daniel S. Gold, Ph.D., CEO.